AVASCULAR NECROSIS MARKET ANALYSIS

Avascular Necrosis MarketSize and Trends

The global avascular necrosis market is estimated to be valued at US$ 605.0 Mn in 2021 and is expected to exhibit a CAGR of 6.0% over the forecast period (2021-2028).

Increasing number of drug approvals from regulatory bodies is a major factor driving the global avascular necrosis market growth over the forecast period

Market players are focusing on gaining drug approvals from regulatory bodies, which is expected to drive the growth of global avascular necrosis market during the forecast period. For instance, in December 2020, Novartis AG, a pharmaceutical company, announced that the European Commission (EC) had approved Leqvio (inclisiran) for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. Leqvio is a first-in-class small interfering RNA (siRNA) providing effective and sustained LDL-C reduction for patients with atherosclerotic cardiovascular disease (ASCVD).  

Increasing number of product launches by the market players is expected to drive the global avascular necrosis market growth during the forecast period

Increasing number of partnerships by key players are expected to boost the market growth of the global avascular necrosis market during the forecast period. For instance, in August 2021, Dr. Reddy’s Laboratories Ltd., a pharmaceutical company announced the re-launch of over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, the store-brand equivalent of Aleve, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).

 Figure 1: Global Avascular Necrosis Market Share (%) Analysis, By Drug Type, 2021

Figure 2: Global Avascular Necrosis Market Value (US$ Mn), by Region, 2020